Although no effective targeted treatment for this resistance mutation is yet available, its detection is gaining relevance since third-generation EGFR inhibitors have become standard for up-front treatment of EGFR-mutated NSCLC [36]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.